Amiens Cedex 1

• DASSOH - Systematic use of DDAVP to prevent serum sodium overcorrection in severe hyponatremia : a multicenter open-label randomized control … Recruiting
  2023-507254-32-00 5 2024-12-17 Severe hyponatremia and a high risk of rapid SNa overcorrection
• Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroe … Recruiting
  2023-508724-35-00 4 2024-12-10 Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectu
• This is a study to evaluate safety and efficacy of Upadacitinib comparing to Dupilumab in children from 2 to less than 12 years of age with … Recruiting
  2023-504713-76-00 5 2024-12-03 Dermatitis atopic
• Effect of nonsteroidal anti-inflammatory drugs in the management of postoperative pain after cardiac surgery: A multicentre, randomised, pla … Recruiting
  2023-506299-28-00 6 2024-12-02 Postoperative pain after cardiac surgery
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-fibrosis) Recruiting
  2023-509912-27-00 5 2024-11-07 Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
• Induction therapy for lupus nephritis with no added oral corticosteroids : An open label randomised multicentre controlled trial comparing … Recruiting
  2024-516242-19-00 5 2024-11-05 lupus nephritis
• Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg … Recruiting
  2023-504620-26-00 4 2024-11-04 Triple negative breast cancer
• Multicenter randomized, double-blind, placebo controlled trial evaluating the effect of a 30-week caffeine treatment on cognition in early-t … Recruiting
  2024-514099-41-00 5 2024-10-31 Alzheimer's disease
• Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (ENLIGHTEN-Cirrhosis) Recruiting
  2023-510395-31-00 5 2024-10-30 Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
• Reduction in the number of chemotherapy cycles in combination with Pembrolizumab in first-line treatment of PD-L1-positive recurrent or meta … Recruiting
  2024-514875-16-00 4 2024-10-21 First-line treatment of PD-L1-positive recurrent or metastatic head an
• Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting
  2023-504724-25-00 5 2024-10-16 Primary Myelofibrosis
• FLUOCOL-1 : Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage Recruiting
  2024-515118-42-00 11 2024-09-10 Colorectal cancer
• Prospective study in patients with colon or rectum cancer with liver metastasis of the efficacy and toxicity of standard therapy (chemothera … Recruiting
  2024-517204-11-00 4 2024-08-30 microsatellite stable (MSS) colorectal cancer with liver-dominant meta
• PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting
  2024-515297-27-00 5 2024-08-14 colon carcinoma
• Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu … Recruiting
  2024-515788-73-00 4 2024-07-30 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IM
• Personalized medicine for advanced biliary cancer patients Recruiting
  2023-508100-38-00 5 2024-06-24 Advanced Biliary Cancer (ABC)
• Intraoperative Sufentanil and chronic postsurgical pain in non-major scheduled abdominal surgery Recruiting
  2023-510140-21-00 6 2024-06-24 Chronic postsurgical pain in non-major scheduled abdominal surgery
• FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and … Recruiting
  2023-506590-35-00 4 2024-06-13 Large-Cell NeuroEndocrine Carcinoma of the lung
• Comparison of Vedolizumab treatment to Adalimumab dose intensification in Crohn’s disease patients with loss of response or biomarker activi … Recruiting
  2023-508154-25-00 6 2024-05-27 Crohn's disease
• Neoadjuvant Chemotherapy for Obstructive Colon cancER first Treated by cOlostomy : A randomized phase III trial - COnCERTO (French 01-18) 20 … Recruiting
  2024-516456-17-00 5 2024-05-07 patients admitted for an obstructive colon cancer
• Phase 3 study to assess the efficacy and safety of Givinostat versus hydroxyurea in Polycythemia Vera patients Recruiting
  2022-502276-23-00 5 2024-04-25 JAK2V617F-positive high-risk Polycythemia Vera
• Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first-line treatment for patients with PD-L1 CPS ≥5 metas … Recruiting
  2023-506753-38-00 4 2024-04-16 metastatic gastric adenocarcinoma

Showing 145–168 of 317 trials